Compumedics Limited (ASX:CMP) Achieves Record Sales and Returns to Profitability
Compumedics Limited (ASX:CMP) reports record FY25 sales and returns to profitability, highlighting strong US traction and SaaS growth.
Category: Healthcare
Proteomics International Laboratories Ltd (ASX:PIQ) Announces Breakthrough in Equine Muscle Recovery Testing
Proteomics International (ASX:PIQ) unveils the OxiDx test for detecting muscle damage in racehorses, targeting an Australian launch in H2 CY25.
Imugene Limited (ASX:IMU) Announces Positive Phase 1b Trial Results for Azer-cel
Imugene Limited (ASX:IMU) reports 75% response rate in Phase 1b trial of azer-cel for relapsed diffuse large B-cell lymphoma.
Orthocell Limited (ASX:OCC) Reports First US Remplir™ Sales Revenue
Orthocell (ASX:OCC) records first US sales revenue from Remplir™ nerve repair product, marking a significant milestone in US expansion.
Mach7 Technologies Limited (ASX:M7T) Updates FY25 Guidance and Share Buyback
Mach7 Technologies (ASX:M7T) updates its FY25 guidance, initiates a share buyback, and announces an investor webinar with the new CEO.
Biome Australia Limited (ASX:BIO) Announces Record Sales Revenue
Biome Australia Limited (ASX:BIO) reports a 41% revenue increase in FY25, highlighting strong performance in Q4 and June.
Botanix Pharmaceuticals (ASX:BOT) Reports Strong Sofdra™ Launch Performance
Botanix Pharmaceuticals (ASX:BOT) reports $25M AUD in Sofdra™ sales and expansion of prescriber network, signaling strong market performance.
Nova Eye Medical Limited (ASX:EYE) Achieves Record Revenues for FY25
Nova Eye Medical Limited (ASX:EYE) reports record FY25 revenues of A$28.8m, driven by strong US sales and highest Q4 sales on record.
Nanosonics Limited (ASX:NAN) Launches trophon3 and trophon2 Plus
Nanosonics Limited (ASX:NAN) launches trophon3 and trophon2 Plus, enhancing infection prevention with faster disinfection and advanced digital integration.
Imugene Limited (ASX:IMU) Receives $5.8m R&D Tax Refund
Imugene Limited (ASX:IMU) receives a A$5.8m R&D tax refund to advance its immuno-oncology pipeline.